Summary
Medtronic plc reported solid financial results for the first quarter of fiscal year 2018, with net sales increasing by 3% to $7.39 billion, driven by growth across its Cardiac and Vascular, Minimally Invasive Therapies, and Restorative Therapies segments. Net income attributable to Medtronic rose by 9% to $1.016 billion, or $0.74 per diluted share, compared to the same period last year. The company also saw a significant increase in operating profit, up 19% year-over-year, indicating strong operational performance and effective cost management. Acquisitions, including HeartWare, contributed to sales growth, while strategic initiatives like cost synergies from the Covidien acquisition and global footprint optimization continued to support margin expansion. The company successfully managed its restructuring and acquisition-related charges, with divestiture-related expenses also noted. Medtronic's balance sheet remains robust, with total assets at $100.25 billion. The company also demonstrated its commitment to shareholder returns through share repurchases and dividend payments. Despite some headwinds from currency fluctuations and ongoing litigation expenses, Medtronic's diversified business model and focus on innovation position it well for continued growth.
Financial Highlights
53 data points| Revenue | $7.39B |
| Cost of Revenue | $2.35B |
| Gross Profit | $5.04B |
| SG&A Expenses | $2.58B |
| Operating Income | $1.38B |
| Interest Expense | $286.00M |
| Net Income | $1.02B |
| EPS (Basic) | $0.75 |
| EPS (Diluted) | $0.74 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.38B |
Key Highlights
- 1Net sales increased 3% year-over-year to $7.39 billion.
- 2Net income attributable to Medtronic grew 9% to $1.016 billion.
- 3Diluted earnings per share increased to $0.74 from $0.66.
- 4Operating profit saw a significant increase of 19% to $1.389 billion.
- 5Cardiac and Vascular Group and Minimally Invasive Therapies Group reported 5% and 3% net sales growth, respectively.
- 6The company completed the divestiture of its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses on July 29, 2017, for $6.1 billion.
- 7Medtronic returned approximately $1.7 billion to shareholders through dividends and share repurchases during the quarter.